Clinical trials: UCART
Diffuse Large B-cell Lymphoma
CTA101 in the Treatment of Relapsed or Refractory Diffuse Large B-cell Lymphoma
This is a single-center, non-randomized and dose-escalation study to evaluate the safety and efficacy of CTA101 in relapsed or refractory diffuse large B-cell lymphoma patients.
- Trial name
- NCT04026100
- Testing
- CTA101
- Where
- China
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Multiple Myeloma
Efficacy and Safety Evaluation of BCMA-UCART
This trial aims to evaluate the safety and efficacy of BCMA-UCART in treating patients with relapsed or refractory multiple myeloma.
- Trial name
- NCT03752541
- Testing
- BCMA-UCART
- Where
- China
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Bioray Laboratories
Peripheral Blood Mononuclear Cell
Peripheral Blood Mononuclear Cell Collection Protocol for UCART Cell Tumor Immunotherapy Study
Peripheral blood mononuclear cell collection protocol for tumor immunotherapy study of UCAR-T cells
- Trial name
- NCT04448509
- Testing
- Peripheral blood mononuclear cell apheresis
- Where
- China
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- He Huang